Cutaneous BCG of the penis after intravesical therapy for bladder cancer: a case report in a 66-year-old male.
OBJECTIVE
Transitional cell carcinoma of the bladder is commonly treated with intravesical BCG. We report a cutaneous complication of BCG after therapy in 66-year-old male 4 years after initiating treatment.


METHODS
A case review including pathological slides, laboratory data, and radiographic findings.


RESULTS
Biopsy findings showed an ill defined granulomatous process with chronic inflammation and necrosis.


CONCLUSIONS
The patient was managed on antituberculous therapy for a period of 6 months with resolution of symptoms.
Hillyer
Shahab
S
Department of Urology, Brookdale University Hospital and Medical Center, Brooklyn, New York, USA.
Gulmi
Frederick A
FA
D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000009:adverse effects; D000283:Administration, Intravesical; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage / Q000009:adverse effects*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy; D003937:Diagnosis, Differential; D006801:Humans; D008297:Male; D009164:Mycobacterium Infections / Q000139:chemically induced* / Q000175:diagnosis / Q000382:microbiology; D009163:Mycobacterium bovis / Q000302:isolation & purification*; D010409:Penile Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000382:microbiology; D010413:Penis / Q000382:microbiology*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine